AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01412879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT03399344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
Study NCT04163263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-356
Description: topical gel
Study NCT04163263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical gel
Study NCT00393367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg
Description: Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
Study NCT00393367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone, prednisone, or methylprednisolone
Description: All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO or IV
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given PO or IV
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV
Study NCT01412879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT01322828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal bicep tendon reconstruction
Description: Randomized to either a single incision technique or a double incision technique.
Study NCT01445171 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aortic Valve Replacement with EDWARDS INTUITY Valve System
Description: Aortic Valve bioprosthesis
Study NCT03101072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed long antibiotic course of 14 days
Description: Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
Study NCT02713425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Entertaining Video Game
Description: Children between 7 \& 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
Study NCT04019834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regional nerve block with local anesthesia of bupivacaine with steroid
Description: Patient will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes for either pectoral, serratus, or erector spinae nerve blocks. A block needle will be passed into the fascial plane and injectate will be deposited. The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.
Study NCT04019834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo regional nerveblock with normal saline
Description: Patients who are randomized to placebo will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue .
Study NCT00665470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks
Study NCT00963482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural smoking cessation program
Description: It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra \& Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
Study NCT00963482 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Autogenic training
Description: Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
Study NCT04030286 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
Study NCT03101072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed short antibiotic course of 7 days
Description: Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
Study NCT03101072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized duration of antibiotic therapy
Description: Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
Study NCT01715844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: Patients will take 3-gr of L-citrulline/day for 7 days
Study NCT01715844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline
Description: Patients will take 3-gr of L-citrulline/day for 7 days
Study NCT00468715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT00468715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Study NCT00468715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT02058121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT is provided in 12 weekly two hour long sessions in a group setting
Study NCT02058121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
Study NCT02976506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise program
Description: Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
Study NCT02976506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical fitness and quality of life
Description: Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to \< 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
Study NCT03415230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Description: Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
Study NCT03415230 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham massage
Description: Sham massage involves only light touch massage in a non systematic way
Study NCT00390832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: 33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
Study NCT00390832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
Study NCT03463330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Description: The Qigong exercise is a series of mild exercise movements.
Study NCT03463330 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mild body exercise
Description: Participants will be taught of series of similar movements to the Qigong exercise.
Study NCT00142506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate and questionaires
Description: Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
Study NCT00142506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets and questionaires
Description: Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
Study NCT02807077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
Study NCT03217162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surfactant combined with mechanical ventilation (MV)
Description: surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
Study NCT03217162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation (MV)
Description: mechanical ventilation (MV) is given to the infant with ARDS
Study NCT04578210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T memory cells and NK cells
Description: Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).
Study NCT02101437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA within 24hr
Description: miRNA within 24hr
Study NCT02101437 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: miRNA within 24hr
Description: miRNA within 24hr
Study NCT02101437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 week
Description: miRNA after 1 week
Study NCT02101437 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: miRNA after 1 week
Description: miRNA after 1 week
Study NCT02101437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: miRNA after 1 month
Description: miRNA after 1 month
Study NCT00393367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone, prednisone, or methylprednisolone
Description: All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
Study NCT01816763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRS pain one week
Description: Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
Study NCT01816763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEG
Description: Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
Study NCT01816763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVPRS
Description: Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
Study NCT00393367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol, ipratropium bromide
Description: While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
Study NCT02101437 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: miRNA after 1 month
Description: miRNA after 1 month
Study NCT02993237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI FDC placebo tablet
Description: Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
Study NCT02993237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC placebo tablets
Description: Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
Study NCT02065778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
Study NCT04057170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accelerated protocol and mulligan method
Description: manual therapy technic
Study NCT03018015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg oral powder
Study NCT03018015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg film-coated tablet
Study NCT03018015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg soft capsule
Study NCT02528344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
Study NCT02687308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Retrograde radical prostatectomy RRP
Description: This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
Study NCT02687308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 Anterograde radical prostatectomy RRP2A
Description: This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
Study NCT04246554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Oral ketorolac for pain control following ACL reconstruction surgery
Study NCT00393367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol, ipratropium bromide
Description: While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
Study NCT00393367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: 500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
Study NCT04246554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone-Acetaminophen
Description: Oral oxycodone-acetaminophen for post-operative pain control
Study NCT01258920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
Study NCT04574999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol
Description: Gel for vaginal application
Study NCT04574999 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel for vaginal application
Study NCT04746326 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Failure conservative treatment
Description: Surgery was performed in patients who failed conservative treatment.
Study NCT04746326 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Surgery was performed in patients who had generalized peritonitis and perforation.
Study NCT00393367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium bromide
Description: 500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
Study NCT02320409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: 250mg Sulfatinib ,single dose,oral